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Summary
The failure of the AJCC/UICC staging system in predicting prognosis in intermediate-stage of 
colorectal cancers (CRCs) may be overcome by adding tumor budding (TB) in pathology report 
as the presence of high-grade TB has been consistently associated with negative clinicopat-
hologic parameters in gastrointestinal tumors, especially in CRCs. Over the past few decades, 
numerous methods of assessing TB in CRC have been proposed, with variations in the area of 
assessment, cut-off values, and use of standard hematoxylin and eosin (H&E) stained slides vs. 
cytokeratin immunohistochemistry. This review summarizes previous studies in this scientific 
area and resulting guidelines. The concept of whether peritumoral budding (PTB) vs. intratumo-
ral budding (ITB), or both, should be assesed is still under discussion. The original studies on TB 
utilized PTB, or assesment of budding at the invasive front of the CRC, and current guidelines 
pertain to that. Budding category and tumor grade are not the same and TB has an independent 
prognostic value and should be taken into account along with other clinicopathological factors in 
a multidisciplinary setting. TB should be routinely reported in stage II CRC, next to other high-risk 
factors, in order to aid the decision for adjuvant therapy.
Keywords: colorectal cancer; tumor budding; pathology report; peritumoral budding; intra-
tumoral budding.
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INTRODUCTION
Adenocarcinoma of the colon represents 98% of colonic cancers and is the 
most common primary colon carcinoma (1). Globally, and for high sociodemo-
graphic index (SDI) countries, colon and rectal cancer ranked third for cancer in-
cidence and second for cancer death in 2015. Colon and rectum cancer incidence 
ranked lowest in low SDI countries as the eighth most common cancer and was 
the sixth leading cause for cancer mortality. Between 2005 and 2015, incidence 
increased by 37% and is of special concern (2). Stage is the most important pro-
gnostic factor (1). With the rise of personalized medicine, accurate pathology re-
porting of colorectal cancer (CRC) resection specimen is crucial because it gives 
essential information that helps plan the treatment of individual patients and 
contains some key prognostic parameters (3,4).
Tumor staging according to the American Joint Committee on Cancer (AJCC)/
Union for International Cancer Control (UICC) tumor, node, metastasis (TNM) 
system is currently regarded as the standard for staging of CRC. The TNM cla-
ssification provides the strongest prognostic information for patients with early 
stage disease and those with advanced disease. It is less efficient in predicting 
disease outcome for patients with intermediate levels of disease (5,6).
The failure of the AJCC/UICC staging system in predicting prognosis in in-
termediate-stage tumors may be overcome by adding additional factors, either 
morphological, molecular or treatment-related, which could stratify patients 
more precisely into different risk categories (7-9). Among morphological tumor-
related factors, tumor budding has been shown to be a strong prognostic factor 
in CRC (10). The first description of what we now call tumor budding (TB) was 
by Imai in the article from 1954, as “sprouting” at the invasive edge of carcino-
mas (11,12).
TUMOR BUDDING - NEW STANDARD ELEMENT IN COLORECTAL 
CANCER PATHOLOGY REPORT?
Tumor buds are thought to result from the process known as epithelial-me-
senchymal transition (EMT), (13). The EMT process, by allowing a polarized cell 
to assume a more mesenchymal phenotype with increased migratory capacity, 
invasiveness, and resistance to apoptosis, seems to play a major role in the de-
velopment of tumor buds. In fact, TB reflects a process of dedifferentiation, and 
represents the histologic hallmark of EMT (14).
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EMT is a process of cellular plasticity first discovered in embryonic deve-
lopment and reflects a reversible embryonic program and was later recognized 
to play an important role in cancer propagation (15-18). EMT is recognized as a 
driving force of cancer cell metastasis and drug resistance, two leading causes 
of cancer recurrence and cancer-related death (19). Induction of EMT has been 
shown to contribute significantly to chemoresistance in CRC (20). Cells under-
going EMT loose the apical-basal polarity of epithelial cells, downregulate cell 
adhesion molecule expression and induce the expression of vimentin filaments, 
fibronectin and N-cadherin. In EMT there is loss of E-cadherin, a homophilic 
calcium dependent cell adhesion molecule located in the adherents junctions of 
epithelia. Loss of E-cadherin expression is correlated with increased invasivene-
ss of cancer cells. Reduced E-cadherin expression occurs when the zinc finger 
containing proteins Slug, Snail and SIP1 or the basic helix-loop-helix gene called 
Twist downregulate the E-cadherin promoter by binding to a series of inhibitory 
E-box sites (21). 
Tumor buds in colorectal carcinoma show downregulation of adhesion pro-
tein E-cadherin, accompanying nuclear translocation of beta-catenin, and loss 
of cell polarity with acquisition of fibroblastoid morphology as demonstrated by 
Brabletz et al. in 2001 (22). 
Tumor budding is defined as single cells or clusters of up to four cells at the 
invasive margin of CRC and can be stratified into peritumoral budding (PTB, 
tumor buds at the tumor front) and intratumoral budding (ITB, tumor buds in 
the tumor center) (23,24). The presence of high-grade TB has been consistently 
associated with negative clinicopathologic parameters in gastrointestinal tu-
mors, especially in CRCs (10,23,25-27).
A study by Hase et al. in 1993 first adopted the phrase “tumor budding”, 
and showed a dramatic decrease in survival with increased budding in colo-
rectal carcinoma (5-year survival of 22 vs. 71%, p<0.001). This first definition of 
budding was subjective, with budding defined as small clusters of cells at the 
invasive front, and budding classified into none or mild (BD-1) and moderate or 
severe (BD-2), (28).
Over the past few decades, numerous methods of assessing TB in CRC have 
been proposed, with variations in the area of assessment, cut-off values, and 
use of standard hematoxylin and eosin (H&E) stained slides vs. cytokeratin 
immunohistochemistry (12). Puppa et al. demonstrated that in a multicentre, 
multinational study in 2012 where they assessed the diagnostic reproducibility 
of five methods (10,14,23,26-29). We updated and modified the table represented 
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in the respective article (14) and included some other results reported by other 
authors (10,14,23,26-31), (Table 1). They also concluded that cytokeratin immuno-
histochemistry (IHC) with CK AE1/AE3 antibody detected a higher percentage 
of TB-positive cases with all methods compared to H&E-stained slides, but did 
not influence agreement levels.
The Ueno method was elaborated again in 2008 (32), introducing the grading 
system for colorectal carcinoma based upon quantification of „areas of poorly 
differentiated components“, and again further in 2012 (31), introducing the gra-
ding system based upon quantification of „poorly differentiated clusters“, which 
are morphologically closely related to TB (the nests are slightly larger) and also 
the micropapillary variant of colorectal carcinoma. Future studies are needed to 
prove the originality of poorly differentiated clusters as a histological feature as 
well as a prognostic variable (5).
The concept of whether PTB vs. ITB, or both, should be assesed is still under 
discussion (12). The original studies on TB in pT1 colorectal carcinoma utilized 
PTB, or assesment of budding at the invasive front of the carcinoma (23,28). The 
idea of ITB was introduced in 2011 in the context of preoperative biopsies of co-
lorectal carcinoma (33), however, it was first reported in 1989 in a series of rectal 
cancer biopsies and found to be associated with lymph node metastases (34). 
In 2017 Lugli et al. reached an agreement that gave way to the latest re-
commendations for tumor reporting in CRC based on the International tumor 
budding consensus conference (ITBCC) that was held in 2016 (35). Basically, it 
is the Ueno method, with some modifications. They emphasized the value of 
both ITB and PTB – both are morphologic manifestations of EMT. But while 
PTB can only be assessed in surgical resection specimens, ITB can be assessed 
in both CRC biopsies and resection specimens. In recent studies, ITB present in 
preoperative biopsies has shown a correlation with high-grade PTB, lymph node 
metastases and tumor regression grade in the corresponding colorectal cancer 
resection specimens (33,36,37). However, the ITBCC group agrees that the qu-
ality of evidence relating ITB in colorectal cancer to lymph node metastasis re-
mains low. Although ITB may prove to be a promising biomarker in the preope-
rative management of CRC-patients, there is insufficient evidence to support its 
routine reporting at this time. The ITBCC group therefore recommends further 
research in this area before reporting of ITB is implemented in routine practice.
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The method of TB reporting in CRC by ITBCC group is as follows (35):
1. The field (specimen) area for the 20x objective lens of your microscope 
based on the eyepiece field number (FN) diameter should be defined 
with the conversion table (35). 
2. H&E-stained slide with greatest degree of budding at the invasive front 
should be selected
3. Scan 10 individual fields at medium power (10x objective) to identify the 
“hotspot” at the invasive front (for pT1 endoscopic resections all fields 
should be scanned - usually <10 fields available)
4. Count tumor buds in the selected “hotspot” (20x objective)
5. Divide the bud count by the normalization factor for your microscope to 
determine the tumor bud count per 0.785mm2
6. The budding (Bd) category based on bud count and indicate the absolute 
count per 0.785mm2 should be selected: Bd1 (low) – 1-4 buds, Bd2 (inter-
mediate) – 5-9 buds, Bd3 (high) – ≥10 buds.
Although the final tumor bud count is performed on H&E, the ITBCC group 
claims that IHC can be helpful in challenging cases (ie, glandular fragmenta-
tion, strong peritumoral inflammation, reactive stromal cells) to confirm that 
the cells being counted are indeed tumor buds, although IHC may also stain 
apoptotic bodies and cellular debris, which should not be counted as buds. H&E 
recommendations might change as more data on IHC assessment become avai-
lable (Figure 1).
The ITBCC group agrees that TB category and tumor grade are not the same, 
that TB has an independent prognostic value and should be taken into account 
along with other clinicopathological factors in a multidisciplinary setting (TNM 
classification, prognostic factors such as tumor grade, histological subtype, vas-
cular invasion, perineural invasion, margin status, molecular biomarkers such 
as microsatellite, KRAS mutation and BRAF mutation status). The ITBCC group 
considers the prognostic value of TB category to be at least equivalent to that of 
vascular invasion, tumor grade and perineural invasion status, and therefore 
recommends that TB should be taken into account along with these and other 
clinicopathologic factors in the risk assessment of CRC and be included in gu-
idelines/protocols for CRC reporting.
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Figure 1. Tumor budding at the invasive front of the adenocarcinoma of the colon. (A) H&E stain, 
magnification 200x, vertical arrows show tumor buds which are hardly seen in strong peritumoral 
inflammation of the adenocarcinoma of the colon, horizontal arrow shows cluster of at least 5 cells 
which exceeds the size of tumor bud; (B) Immunohistochemical analysis (CK AE1/AE3 stain) in the 
same tumor, magnification 200x.
TUMOR BUDDING AS A COLORECTAL CANCER PROGNOSTIC 
FACTOR
TB is also of interest in distinct subgroups of CRC as a prognostic factor 
(5,12,35). It is associated with a higher TNM stage, high tumor grade, the presen-
ce of lymphovascular invasion and consequently with lymph node and distant 
metastases (38-42). Berg and Schaeffer presented a summary of key studies on 
TB in pT1 and stage II colorectal carcinoma in a review article that recently appe-
ared on Modern Pathology web site (12). 
In early lesions (pT1), it appears to be one of the strongest parameters asso-
ciated with the presence of regional lymph node spread (5,43,44). In fact, high-
grade TB has been well established as one of the pathologic prognostic criteria 
that carry increased risk for lymph node metastases, and therefore, need for 
surgery post polypectomy (12,23,28,29,45,46). TB carried a relative risk of 5.1 for 
lymph node metastasis, in addition to lymphatic invasion, submucosal invasi-
on depth of >1 mm and poor histological differentiation (12,44). By the ITBCC 
group, in pT1 CRC, Bd2 and Bd3 are associated with an increased risk of lymph 
node metastasis (35). The Japanese Society for Cancer of the Colon and Rectum 
(JSCCR) has incorporated TB into „JSCCR Guidelines 2016“ (47), for which pT1 
carcinoma patients require subsequent surgery (along with vascular invasion, 
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high grade and submucosal depth of invasion >1000 µm), using their consensus 
method for assessment of budding, and applying a cut-off of 5 or more buds 
(intermediate and high-grade categories – G2/3) as an independent predictor of 
lymph node metastasis. „Japanese method“ for TB assessment is the same as the 
ITBCC group’s, with Ueno and Ajioka being the same authors in both articles 
(35,47).
In patients with AJCC/UICC stage II disease (which encompasses a group 
of patients with T3-T4 tumors and no lymph node metastases), the extent of TB 
could be used to select patients with node-negative cancers for adjuvant therapy 
(5,28,12,38,48,49). Although some of these patients are cured with surgery, a su-
bset of these patients have a substantial risk of recurrence (50). TB has been well 
established as a poor prognostic factor in stage II colorectal carcinoma (12,48,51). 
A systematic review by Petrelli et al. in 2015 (52) showed high-grade budding to 
be a significant poor prognostic factor with an odds ratio of 6.25 for mortality. 
The ITBCC group agrees that TB grade is an independent predictor of survival 
in stage II CRC and that Bd3 is associated with an increased risk of recurrence 
and mortality (35). Patients with stage III CRC are generally offered adjuvant 
chemotherapy, whereas those with stage II are not, unless other high-risk featu-
res are present (ie, tumor perforation, lymphovascular invasion, serosal involve-
ment – pT4a, poor tumor differentiation in microsatellite stable tumors, close/in-
determinate/positive margins, perineural invasion and low lymph node yield). 
However, some stage II CRC patients show worse survival than stage III patients 
who receive adjuvant chemotherapy (53-55). Numerous studies have shown TB 
to be an independent predictor of recurrence and survival in stage II CRC with 
outcomes similar to stage III colorectar cancer (35). 
High-grade TB has also been reported to predict non-responders to anti-
EGFR therapies, along with K-Ras mutation status. Of interest in that study, low-
grade TB was 100% predictive of response to EGFR therapy, with all low-grade 
budding having at least partial response, and no progressive or even stable di-
sease (12,56).
CONCLUSION
We conclude that tumor budding should be routinely reported in stage II 
CRC, next to other high-risk factors, in order to aid the decision for adjuvant 
therapy, along with ITBCC group recommendation that in addition to the Bd 
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category the absolute bud count should also be provided, as this avoids loss of 
information that may occur when applying a cut-off to borderline cases.
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Sažetak
Tumorsko pupanje u karcinomu debelog crijeva i rektuma
Neuspjeh AJCC/UICC staging sustava u predviđanju prognoze u srednjem stadiju karcinoma 
debelog crijeva i rektuma (KDCR) može se prevladati dodavanjem tumorskog pupanja (TP) u 
nalaz patologa jer je prisutnost visokog gradusa TP dosljedno povezivana s negativnim klinikopa-
tološkim parametrima u gastrointestinalnih tumora, posebno u KDCR. Tijekom proteklih nekoliko 
desetljeća predložene su brojne metode procjene TP u KDCR, s varijacijama područja procjene, 
graničnim vrijednostima i korištenjem standardnih hematoksilin-eozinom obojenih preparata na-
suprot imunohistokemiji citokeratinom. Ovaj pregledni članak sažima dosadašnja istraživanja 
u ovom znanstvenom području i proizašle smjernice. Još uvijek se razmatra koncept treba li 
se procjenjivati peritumorsko pupanje (PTP) ili intratumorsko pupanje (ITP), ili oboje. Izvorne 
studije o TP-u koristile su PTP ili procjenu pupanja na invazivnom rubu KDCR, a trenutne se 
smjernice odnose na to. Kategorija pupanja i stupanj tumora nisu isti, a TP ima nezavisnu pro-
gnostičku vrijednost te ga treba uzeti u obzir zajedno s drugim kliničkopatološkim čimbenicima 
u multidisciplinarnom okruženju. TP bi trebalo rutinski izvijestiti u stadiju II KDCR, pored drugih 
visokorizičnih čimbenika, kako bi se pomogla odluka o adjuvantnoj terapiji.
Ključne riječi: karcinom debelog crijeva i rektuma; tumorsko pupanje; izvještaj patologa; 
peritumorsko pupanje; intratumorsko pupanje.
Corresponding author:
Božo Krušlin
e-mail: bozo.kruslin@gmail.com
